financetom
Business
financetom
/
Business
/
Divi's Laboratories gets GST demand notice of ₹164 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Divi's Laboratories gets GST demand notice of ₹164 crore
Nov 16, 2023 2:37 AM

Hyderabad-based pharmaceutical company Divi's Laboratories Limited on Thursday, November 16, said it has received a Goods and Service Tax (GST) demand notice totalling ₹164 crore, along with interest and penalty. At 11:30 am, the scrip was trading almost flat at ₹3,543 apiece on the NSE.

Share Market Live

NSE

The notice was issued by the Office of the Commissioner of Central Tax, Ranga Reddy GST Commissionerate, Hyderabad, the company said.

The drugmaker does not expect the order to have any material financial impact on it. "The company evaluated the merits of the case and decided to file the appeal with the Appellate Authority within time-limit prescribed under the GST Law," Divi's Laboratories said in a regulatory filing.

"The order pertains to recovery of refund of IGST granted under Rule 96 of CGST Rules, 2017 alleged to have been claimed erroneously in terms of the provisions of the GST Act, 2017 (‘GST Law’). Demand raised: IGST of ₹82,04,24,880 along with applicable interest and penalty of ₹82,04,24,880 being 100% of the tax amount (IGST)," it said.

During the July to September quarter, the pharma company reported a net profit of ₹348 crore, which turned out to be lower than the CNBC-TV18 poll of ₹410.8 crore. On a year-on-year basis, the company's net profit declined by 29.5% from the year-ago period.

While Divi's revenue managed to meet expectations, its operating profit or EBITDA, as well as the EBITDA margin missed Street expectations.

The company's revenue for the period came in at ₹1,909 crore, which was in-line with Street expectations of ₹1,886 crore. Its topline rose 3% as against the same period last fiscal.

The range for revenue growth estimates for Divi's were wide, ranging from a decline of 5% to a growth of 7.4% year-on-year.

Operating profit or EBITDA declined by 22.9% from last year to ₹479 crore from ₹621 crore last year. The figure was well below the CNBC-TV18 poll expectation of ₹570.8 crore.

EBITDA margin narrowed by over 800 basis points to 25.1% from 33.5% last year. A CNBC-TV18 poll had projected the figure at 30.3%.

First Published:Nov 16, 2023 11:37 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CFPB ends monitoring of Apple, U.S. Bank years ahead of schedule
CFPB ends monitoring of Apple, U.S. Bank years ahead of schedule
Sep 22, 2025
(Reuters) -The Consumer Financial Protection Bureau has scraped settlements with Apple ( AAPL ) and U.S. Bank that were implemented under former President Joe Biden's administration, ending oversight requirements years early, according to court filings dated earlier this month. The moves follow efforts by President Donald Trump's administration to minimize CFPB oversight of consumer finance. The Trump administration has also...
Australia's Myer Holdings swings to annual loss, shares tumble
Australia's Myer Holdings swings to annual loss, shares tumble
Sep 22, 2025
(Reuters) -Australia's Myer Holdings ( MYGSF ) on Tuesday swung to a loss for fiscal 2025 after incurring a one-off, non-cash impairment for Myer Apparel Brands goodwill. Shares of the company dropped as much as 23.4% to A$0.49, their lowest level since late-November, 2023. The broader S&P/ASX 200 benchmark index was up 0.2% by 0043 GMT. The department store chain...
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows
Sep 22, 2025
SEOUL (Reuters) -Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly ( LLY ) in the United States for $330 million. In a statement, Celltrion said it aimed to complete the factory acquisition process by year-end in cooperation with its partner. After upgrades and expansions to...
Trump links autism to Tylenol and vaccines, claims not backed by science
Trump links autism to Tylenol and vaccines, claims not backed by science
Sep 22, 2025
* Trump warns against Tylenol use among pregnant women * Tylenol maker, scientists say evidence shows claims are without merit * Leucovorin approval based on inconclusive studies, doctors say (Adds scientist criticism, updated share moves, researchers on) By Jeff Mason, Ahmed Aboulenein and Julie Steenhuysen WASHINGTON, Sept 22 (Reuters) - U.S. President Donald Trump on Monday linked autism to childhood...
Copyright 2023-2026 - www.financetom.com All Rights Reserved